Definium Therapeutics (DFTX) Interest Expenses (2020 - 2026)
Definium Therapeutics (DFTX) posted quarterly Interest Expenses of $58.2 billion for Q1 2026, up 9659395.85% year-over-year from N/an in Q1 2025, and up 5173402.22% quarter-over-quarter from $1.1 million in Q4 2025.
Definium Therapeutics (DFTX) Interest Expenses (2020 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Interest Expenses for 7 consecutive years, with $58.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 9659395.85% year-over-year to $58.2 billion; the TTM figure through Mar 2026 stood at $58.2 billion (up 2372407.75% YoY), while the FY2025 annual figure was $30.9 billion, up 645.12% from the prior year.
- Interest Expenses climbed to $58.2 billion in Q1 2026 per DFTX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $58.2 billion in Q1 2026 and bottomed at $76000.0 in Q1 2023.
- Historically, Interest Expenses has averaged $4.0 billion across 5 years, with a median of $820000.0 in 2023.
- Annual changes were most pronounced in 2023 — Interest Expenses slumped 99.2% — and 2026, when it soared 9659395.85%.
- Definium Therapeutics' Interest Expenses stood at $36.1 million in 2022, then sank by 97.73% to $820000.0 in 2023, then slipped by 20.0% to $656000.0 in 2024, then soared by 71.34% to $1.1 million in 2025, then surged by 5173402.22% to $58.2 billion in 2026.
- Business Quant data shows DFTX's Interest Expenses at $58.2 billion in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | 234.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 234.87 Mn |
| Jun 30, 2026 | 234.87 Mn |
| Mar 31, 2026 | 58.15 Bn |
| Mar 31, 2026 | 58.15 Bn |
| Dec 31, 2025 | 1.12 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 602,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Dec 31, 2024 | 656,000.00 |
| Dec 31, 2024 | 656,000.00 |
| Sep 30, 2024 | 727,000.00 |
| Sep 30, 2024 | 727,000.00 |
| Jun 30, 2024 | 466,000.00 |
| Jun 30, 2024 | 466,000.00 |
| Mar 31, 2024 | 434,000.00 |
| Mar 31, 2024 | 434,000.00 |